{"id":531981,"date":"2021-02-26T20:18:01","date_gmt":"2021-02-26T20:18:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=531981"},"modified":"2021-02-26T20:18:01","modified_gmt":"2021-02-26T20:18:01","slug":"neuroblastoma-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/neuroblastoma-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast_531981.html","title":{"rendered":"Neuroblastoma Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast"},"content":{"rendered":"<div style=\"float:right; width:250px;\" class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/p>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Neuroblastoma Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the Neuroblastoma, historical and forecasted epidemiology as well as the Neuroblastoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n<p style=\"text-align: justify;\">Neuroblastoma is an embryonal malignancy of the sympathetic nervous system arising from neuroblasts (pluripotent sympathetic cells). It originates in the adrenal medulla and paraspinal or periaortic regions where sympathetic nervous system tissue is present.<\/p>\n<p style=\"text-align: justify;\"><strong>Stages of neuroblastoma<\/strong> determine the extent of the spread of the tumor in the patients, and the disease is staged on the basis of results of physical exams, imaging tests, and biopsies of the main tumor and other tissues. The staging of neuroblastoma is based on two classification systems: International Neuroblastoma Staging System (INSS) and International Neuroblastoma Risk Group Staging System (INRGSS).<\/p>\n<p style=\"text-align: justify;\">Neuroblastoma is most common in very young children, but it is rare in children over the age of 10 years. Approximately 1% to 2% of patients with neuroblastoma inherit an increased risk of developing neuroblastoma from their parents.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get FREE sample copy at: <\/strong><br \/><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/neuroblastoma-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/neuroblastoma-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">The <strong>Neuroblastoma market report<\/strong> also covers emerging drugs, current treatment practices, Neuroblastoma market share of the individual therapies, current and forecasted Neuroblastoma Market Size from 2017 to 2030 segmented by seven major markets.&nbsp;<\/p>\n<p style=\"text-align: justify;\">The report provides a detailed current <strong>Neuroblastoma treatment practice\/algorithm<\/strong>, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.&nbsp;<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Neuroblastoma Market\" src=\"https:\/\/www.abnewswire.com\/uploads\/f81a85e20130cb27fa65df4ae17e3790.jpg\" alt=\"Neuroblastoma Market\" \/><\/p>\n<p style=\"text-align: justify;\"><strong>Neuroblastoma Market Key Facts<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The total <strong>Incident population of Neuroblastoma<\/strong> in the seven major markets was observed to be more than 1,500 in 2017.<\/p>\n<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">DelveInsight&rsquo;s estimate suggests a higher<strong> incidence of neuroblastoma<\/strong> in the United States, as compared to EU-5 countries and Japan, with a 629 Incident population in 2017. Furthermore, the incidence rate of neuroblastoma is increasing at a very slow rate in the United States, has stabilized in the EU5, and is decreasing in Japan for the forecasted period, i.e. 2017&ndash;2030.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Japan witnessed more than 250 <strong>incident cases of neuroblastoma<\/strong> in 2017.<\/p>\n<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">As per the study by Heck et al., titled &ldquo;The epidemiology of neuroblastoma: a review,&rdquo; in one North American review of 3,059 cases, 40% of patients were diagnosed in infancy, 89% by age 5 and 98% by age 10. In most countries, boys are diagnosed at rates equivalent to or slightly higher than girls.<\/p>\n<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">As per the study conducted by Shohet et al., titled &ldquo;Epidemiology, pathogenesis, and pathology of neuroblastoma,&rdquo; the median age at diagnosis is 17.3 months, and 40% of patients are diagnosed before one year of age.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Benefits of Neuroblastoma Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Neuroblastoma market report provides an in-depth analysis of <strong>Neuroblastoma Market Size, Share, Trend,<\/strong> Epidemiology and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The Neuroblastoma market report will help in developing business strategies by understanding the <strong>Neuroblastoma Market trends &amp; developments<\/strong>, key players, and future market competition that will shape and drive the Neuroblastoma market in the upcoming years.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The Neuroblastoma market report covers<strong> Neuroblastoma&#8217;s current treatment practices<\/strong>, emerging drugs, market share of the individual therapies in 7 MM.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides a detailed assessment of the <strong>Neuroblastoma market<\/strong> in terms of market drivers &amp; barriers, Unmet Needs, market opportunities, patient population,&nbsp; comparative analysis of pipeline products with detailed clinical profiles, and other factors.&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/neuroblastoma-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Neuroblastoma Market<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>As per Delveinsight, the Neuroblastoma market size is expected to show positive growth, mainly attributed to increased incidence and also due to the expected launch of emerging therapies during the forecast period.<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Neuroblastoma market outlook<\/strong> section of the report helps to build a detailed comprehension of the historic, current, and forecasted Neuroblastoma market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report gives a thorough detail of the <strong>Neuroblastoma market trend<\/strong> of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Neuroblastoma Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">Among the European countries, France has the highest <strong>Incident population of Neuroblastoma<\/strong> with 156 cases, followed by the United Kingdom which has an Incident population of 147 in 2017. On the other hand, Spain has the lowest Incident population of 90 cases in 2017.<\/p>\n<p style=\"text-align: justify;\">The <strong>Neuroblastoma epidemiology<\/strong> section covers insights about the historical and current Neuroblastoma patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Neuroblastoma Drugs Uptake and Key Market Players<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Neuroblastoma Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Neuroblastoma market or expected to get launched in the market during the study period. The analysis covers Neuroblastoma market uptake by drugs; patient uptake by therapies; and sales of each drug.&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Report&rsquo;s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.<\/p>\n<p style=\"text-align: justify;\">Companies across the globe are thoroughly working towards the development of new <strong>treatment therapies for Neuroblastoma<\/strong>. While some of the companies have recently shifted their focus towards this indication, which is expected to create a significant influence on the market size during the forecast period.<\/p>\n<p style=\"text-align: justify;\"><strong>Neuroblastoma companies:<\/strong><br \/>Y-mabs therapeutics<br \/>Clarity Pharmaceuticals<br \/>Autolus Therapeutics<br \/>United Therapeutics Corp<br \/>EUSA Pharma<br \/>And many others<\/p>\n<p style=\"text-align: justify;\"><strong>Neuroblastoma therapies covered in the report include:<\/strong><br \/>Naxitamab<br \/>Omburtamab<br \/>SARTATE<br \/>AUTO6NG<br \/>Unituxin<br \/>Qarziba<br \/>And many more<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Neuroblastoma Competitive Intelligence Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Neuroblastoma Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Neuroblastoma Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Neuroblastoma Patient Journey<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Neuroblastoma Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Neuroblastoma Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Neuroblastoma Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Key Endpoints of Neuroblastoma Treatment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Neuroblastoma Marketed Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Neuroblastoma Emerging Therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Neuroblastoma Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Attribute Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Neuroblastoma Market Outlook (7 major markets)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Neuroblastoma Access and Reimbursement Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. KOL Views on the Neuroblastoma Market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Neuroblastoma Market Drivers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Neuroblastoma Market Barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em><strong>*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/strong><\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Related Reports<br \/><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/neuroblastoma-epidemiology-forecasthttps:\/\/www.delveinsight.com\/report-store\/neuroblastoma-epidemiology-forecast?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\">Neuroblastoma Epidemiology Forecast&nbsp;<br \/><\/a><\/strong>DelveInsight&#8217;s Neuroblastoma &#8211; Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Neuroblastoma in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/neuroblastoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\">Neuroblastoma Pipeline Insights<br \/><\/a><\/strong>Neuroblastoma Pipeline Insight, 2020 report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Neuroblastoma market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Latest BioPharma Blog &#8211;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/blog\/hypofibrinogenemia-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Hypofibrinogenemia Treatment Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<br \/><\/strong><strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=neuroblastoma-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd. 2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=neuroblastoma-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP DelveInsight&#8217;s &#8220;Neuroblastoma Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the Neuroblastoma, historical and forecasted epidemiology as well as the Neuroblastoma market trends in the United States, EU5 (Germany, Spain, Italy, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/neuroblastoma-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast_531981.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-531981","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/531981","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=531981"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/531981\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=531981"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=531981"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=531981"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}